From Analysis:
Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates
What are the biophysical determinants — RNA binding stoichiometry, post-translational modifications, crowding agents — that shift FUS and TDP-43 from functional liquid-liquid phase-separated condensates to irreversible amyloid-like aggregates, and can in-cell cryo-electron tomography resolve the structural transitions in patient-derived iPSC motor neurons?
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["FUS/TDP-43 Phase Separation
Biophysical Determinants of Aggregation"]
B["Perturbation-First Validation
Condensate Modulator Compounds Testing"]
C["Liquid vs Solid State Readout
FRAP, Rheometry, Super-Resolution"]
D["Aggregation Reversal Confirmation
Amyloid-Forming State Prevention"]
E["Motor Neuron Protection
Phase Separation Stabilization Evidence"]
F["ALS Biophysical Therapy
Condensate-Targeted Drug Discovery"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Theorist position for analysis 52661eaf-79f8-4647-8f48-3389f5af4d59: Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates
Source basis: Fundamental Aspects of Phase-Separated Biomolecular Condensates (Chemical Reviews, 2024, DOI 10.1021/acs.chemrev.4c00138). The stored gap context says: Comprehensive review of biomolecular condensate biophysics identified the liquid-to-solid transition in disease-associated RBPs as a major open question requiring in-cell structural approaches.
Primary hypothesis: RNA-binding protein condensate maturation from reversible ph
Skeptic critique for analysis 52661eaf-79f8-4647-8f48-3389f5af4d59: Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Fundamental Aspects of Phase-Separated Biomolecular Condensates could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: in-vitro condensate rules may not transfer cleanly to crowded, stressed patient neurons.
The debate should reject any claim tha
Domain expert assessment for analysis 52661eaf-79f8-4647-8f48-3389f5af4d59: Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation in a model where the proximal readout can be measured before overt toxicity. Stage 3 should conne
{
"ranked_hypotheses": [
{
"title": "RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation as proximal driver in Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates",
"description": "RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation should produce a measurable proximal phenotype before late disease pathology. The decisive test is time-resolved iPSC motor-neuron perturbations combining RNA stoichiometry, PTM mapping, live-cell condensate tr
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for RNA.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | open
No comments yet. Be the first to comment!